Drugs / anti-p53 T-cell receptor-transduced peripheral blood lymphocytes
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00704938 | Jun 2008 → Aug 2009 | cutaneous melanoma, renal cell carcinoma | National Institutes of Health Clinical Center (CC) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-p53 T-cell receptor-transduced peripheral blood lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00704938 ↗ |
| Modality | Cell therapy | “anti-p53 T-cell receptor (TCR) gene-engineered peripheral blood lymphocytes” NCT00704938 ↗ |
| Route | Intravenous | “Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10\^8 cells to 5 x 10\^10 cells.” NCT00704938 ↗ |
| Target | TP53 | “anti-p53 T-cell receptor (TCR) gene-engineered peripheral blood lymphocytes” NCT00704938 ↗ |